KROS Keros Therapeutics, Inc.
USHealthcareAs of 2026-07-09 16:00
Why KROS matters now
Keros Therapeutics, Inc. (KROS) is a US stock in Healthcare. The latest InvestLog snapshot shows $12.03 with +3.08% on the session and $384.9M in market capitalization; recent performance reads 1-month +7.47% and YTD -47.69%.
The latest financial table shown here is Q1 2026, with revenue of $367.0K, net income of $-23.7M, and EPS of $-0.63. Investors can compare that operating picture with valuation signals such as P/E 4.79 and FCF yield -17.1%.
The latest indexable market news headline is "Keros Therapeutics Appoints Anne Prener to its Board of Directors" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $105.00; recent insider activity includes BIENAIME JEAN JACQUES filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
4.79
PEG
0.03
P/B
1.39
P/S
10.27
EV/EBITDA
-0.85
DCF Value
$-54.38
FCF Yield
-17.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
96.5%
Operating Margin
-332.6%
Net Margin
-256.6%
ROE
-17.0%
ROA
-27.3%
ROIC
-34.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $367.0K | $-23.7M | $-0.63 |
| Q4 2025 | $385.0K | $-23.5M | $-0.38 |
| FY 2025 | $244.1M | $87.0M | $2.30 |
| Q3 2025 | $14.3M | $-7.3M | $-0.18 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$102.60
Target (Median)
$105.00
Target Range
$96.00 - $107.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.96
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.